替吉奥胶囊联合紫杉醇脂质体治疗术后复发胃癌的疗效观察

目的探讨替吉奥胶囊（维康达）联合紫杉醇脂质体全身化疗对术后复发胃癌的近期疗效及不良反应。方法 25例手术后复发胃癌入组,给予替吉奥胶囊联合紫杉醇脂质体方案（替吉奥胶囊按照体表面积给予40～60mg,2次/天,第1～14天；紫杉醇脂质体135mg/m2,第1天静滴90分钟；3周重复）化疗,患者均接受至少2个周期全身化疗后评价疗效。结果总有效率为48%（12/25）,其中完全缓解率8%、部分缓解率40%、稳定率24%,临床获益率达到72%。主要毒副作用有骨髓抑制、周围神经毒性及胃肠道反应。结论替吉奥胶囊（维康达）联合紫杉醇醇脂质治疗术后复发胃癌患者疗效肯定,毒副反应可以耐受。

Clinical observation of S-1 combined with paclitaxel liposome on postoperative recurrence of gastric cancer

Objective To explore for S-1 combined paclitaxel liposome systemic chemotherapy on postoperative recurrence of gastric cancer in the near future curative effect and adverse reactions. Methods 25 cases of gastric cancer recurrence after surgery in group,give combination paclitaxel liposome scheme for S-1（ for S-1 according to body surface area of 40 ～ 60 mg,2 times /d,the first 1 ～ 14 days; paclitaxel liposome（ plain,nanjing Kang Hai pharmaceutical co,LTD.） 135 mg /m2,the first day drop 90 min; 3weeks） systemic chemotherapy patients were receiving at least two cycle after the evaluation of curative effect. Results The total effective rate was 48%（ 12 /25）,of which the complete response rate was 8%,partial remission rate 40%,the stability factor,clinical benefit rate of 72%. The main side effects are bone marrow suppression,peripheral nerve toxicity and gastrointestinal reaction. Conclusion S-1 combined paclitaxel liposome to postoperative patients with recurrent gastric cancer,the curative effect is sure,adverse reaction can be tolerated.